Senolytics and Cellular Senescence Research Compounds: An Overview

Research use only. The compounds discussed on this page are laboratory reagents. They are not medicines, not supplements, and not intended for human or veterinary use, diagnosis, or any application in or on the body. Nothing below is a health claim or a recommendation of any kind.

Senescence has become one of the most heavily studied topics in cell biology over the past fifteen years, and with it a whole category of laboratory compounds has appeared under the label "senolytics". This overview explains what that category actually means in the published literature, which compound classes fall into it, and how a laboratory would treat these materials as reagents. It is a map of a research area, not a guide to using anything.

What are senolytics and cellular senescence

Cellular senescence describes a state in which a cell permanently stops dividing but does not die. The cell stays metabolically active and, in many models, begins secreting a mixture of cytokines, chemokines, proteases, and growth factors that the literature calls the senescence-associated secretory phenotype, usually abbreviated SASP. Senescent cells are commonly identified in vitro and in animal tissue by markers such as p16INK4a, p21, senescence-associated beta-galactosidase activity, and DNA damage markers including gamma-H2AX and 53BP1.

The word "senolytic" was coined to describe compounds reported to selectively trigger apoptosis in senescent cells while sparing proliferating cells. The underlying premise in the published work is that senescent cells evade apoptosis by upregulating specific survival pathways, and that blocking those pathways removes the protection selectively. Different senolytic candidates target different nodes: BCL-2 family proteins, PI3K/AKT signalling, or, in the case of peptide-based candidates, protein-protein interactions such as the FOXO4 to p53 interaction.

A related but distinct term is "senomorphic" or "senostatic", used for compounds reported to dampen the SASP without killing the senescent cell. The two mechanisms are frequently confused in non-academic writing, and researchers designing an assay generally need to state which of the two they are measuring.

Where senolytics sit in the research literature

The senolytic field is almost entirely preclinical. Most of what exists is in vitro work on cultured fibroblasts, endothelial cells, and preadipocytes, plus rodent studies in either naturally aged animals or genetically modified strains that allow senescent cells to be removed on command. Human data is limited to a small number of early-phase investigational studies, and no senolytic compound has regulatory approval anywhere.

Reported preclinical research areas

• Selective apoptosis assays in vitro. Comparing viability of induced-senescent versus proliferating cell populations after exposure to a candidate compound, typically with p16 or SA-beta-gal readouts.
• SASP profiling. Measuring secreted IL-6, IL-8, MMPs, and related factors in conditioned media to distinguish senolytic from senomorphic activity.
• Genetic clearance models. INK-ATTAC and p16-ATTAC mouse lines, in which p16-positive cells can be ablated by a small-molecule dimeriser, used as a benchmark against pharmacological candidates.
• Tissue-specific rodent studies. Reported work in lung fibrosis models, aged hippocampus, renal tissue, and vascular tissue, each with different and sometimes conflicting outcomes.
• Chemotoxicity models. Studies examining senescent cell burden induced by cytotoxic agents such as doxorubicin in animal models.
• Mechanistic structural work. NMR and interaction studies characterising how peptide candidates bind their protein partners.

An important feature of this literature is that it is not uniformly positive. Some published rodent work reports that removing senescent cells can be neutral or harmful depending on tissue and timing, which is discussed further in the regulatory section below.

Compound classes at a glance

Peptide-based candidates

The best known is FOXO4-DRI, a retro-inverso cell-penetrating peptide designed to interfere with the FOXO4 to p53 interaction. Retro-inverso means the sequence is reversed and built from D-amino acids, a common medicinal chemistry approach for improving peptide stability against proteases. It is supplied as a lyophilised powder and is one of the few senolytic candidates that is a peptide rather than a small molecule. The corresponding research-grade material is listed as FOXO4-DRI 10mg.

Flavonoid and small-molecule candidates

Quercetin is a plant flavonoid that appears throughout the senolytic literature, almost always in combination with the kinase inhibitor dasatinib in what published papers abbreviate as "D+Q". Quercetin on its own is more often characterised as a broad polyphenol with antioxidant and kinase-modulating activity in vitro, and the senolytic label applies to the combination rather than to quercetin alone. Fisetin and navitoclax (ABT-263) are the other two small molecules that dominate this part of the field.

Adjacent categories often grouped with senolytics

Several compound families are studied alongside senolytics without being senolytic in the strict apoptosis-inducing sense. Short bioregulator peptides such as Epithalon are studied in telomere and cell-cycle contexts. Mitochondrial and metabolic compounds, covered in the mitochondrial-derived peptides overview, appear in work on mitochondrial dysfunction as an upstream driver of the senescent phenotype. Keeping these categories separate matters when designing an experiment, because the assay endpoints are not interchangeable.

Why the research use only label matters

Every compound named on this page is an investigational research chemical. In the EU these materials are supplied as laboratory reagents under chemical legislation, not as medicinal products under Directive 2001/83/EC. That distinction is what keeps them lawfully available, and it depends entirely on how they are described and sold. A reagent presented with a therapeutic claim or with human use instructions stops being a reagent in the eyes of a regulator and becomes an unauthorised medicinal product.

Regulatory and safety note. No senolytic compound has been approved by the EMA, the FDA, or any comparable authority for any indication. Human safety and efficacy are not established. The preclinical record is also mixed rather than uniformly favourable: published rodent work has reported that clearing senescent endothelial cells can worsen pulmonary haemodynamics in certain models, which underlines that senescent cells serve normal physiological functions in some tissues. Navitoclax, one of the widely cited small-molecule senolytics, carries well-documented platelet toxicity in the oncology literature. These are reasons the field remains experimental.

Handling and storage for researchers

Handling requirements differ sharply between the peptide and small-molecule members of this group.

• Lyophilised peptides. Keep sealed vials at minus 20 degrees Celsius, protected from light and moisture. Allow a vial to reach room temperature before opening so condensation does not form on the cake.
• Reconstituted peptide solutions. Short-term storage at 2 to 8 degrees Celsius, longer-term in aliquots at minus 20 degrees Celsius or below. Aliquot before freezing so that no sample is subjected to repeated freeze-thaw cycles. Our peptide storage and stability guide covers this in more detail.
• Solvent selection. Retro-inverso and cell-penetrating peptides can behave differently from conventional peptides in aqueous buffer. Solubility should be checked at small scale before committing a whole vial. See the bacteriostatic water versus acetic acid comparison for the general trade-offs.
• Flavonoids and small molecules. Quercetin and similar polyphenols are light sensitive and oxidise readily in solution. Amber vials and freshly prepared working solutions are standard practice.
• Documentation. Record lot number, HPLC purity, mass spectrometry identity, and receipt date against each experiment. The certificate of analysis guide explains what to look for on a COA.
• General laboratory practice. Gloves, eye protection, a designated work area, and disposal according to local chemical waste rules.

Frequently asked questions

What does the term senolytic actually mean?

In the published literature a senolytic is a compound reported to selectively induce apoptosis in senescent cells while leaving normally proliferating cells intact. It is a mechanistic description drawn from in vitro and animal work, not a regulatory category and not a statement about any effect in people.

Is any senolytic compound approved as a medicine?

No. As of writing, no senolytic has marketing authorisation from the EMA, the FDA, or any other regulator for any indication. FOXO4-DRI, fisetin, and the dasatinib plus quercetin combination are all investigational. Dasatinib itself is an approved oncology drug, but its use as a senolytic is off-label and experimental.

Are senolytic research compounds legal to buy for research in the EU?

Research-grade FOXO4-DRI and quercetin are supplied within the EU as laboratory chemicals for in vitro and analytical work, provided they are not marketed or labelled for human or veterinary use. The legal position rests on that framing. Individual member states may apply additional controls, and buyers are responsible for confirming the position in their own jurisdiction and for holding an appropriate research context.

How do peptide senolytics differ from small-molecule senolytics in the literature?

Peptide candidates such as FOXO4-DRI are designed to disrupt a specific protein-protein interaction, which in principle gives high target selectivity but brings the usual peptide challenges of stability, cell entry, and cost of synthesis. Small molecules such as navitoclax act on BCL-2 family proteins and are easier to synthesise and store, but the literature associates them with broader off-target activity. Neither class is presented in the published work as clearly superior.

Why is quercetin almost always studied together with dasatinib?

Published work reports that the two compounds cover different senescent cell types, with dasatinib active in some populations and quercetin in others, so the combination is used to broaden coverage in an assay. Papers describing the D+Q cocktail generally do not claim that quercetin alone is senolytic.

How should these compounds be stored?

Lyophilised peptides at minus 20 degrees Celsius, sealed and away from light. Reconstituted material aliquoted and frozen to avoid freeze-thaw cycling. Flavonoids in amber containers with fresh working solutions. Always follow the storage line on the specific certificate of analysis rather than a general rule.

Key takeaways

• Senolytic is a mechanistic label from the preclinical literature, describing selective apoptosis of senescent cells, and it is not a regulatory or therapeutic category.
• The field splits into peptide candidates such as FOXO4-DRI and small molecules such as quercetin in combination with dasatinib, fisetin, and navitoclax.
• Senomorphic compounds, which dampen the SASP without killing the cell, are a separate category and should not be conflated with senolytics in assay design.
• The preclinical record is mixed, with some rodent work reporting harm from senescent cell clearance in particular tissues, so the area remains genuinely open.
• No senolytic is approved anywhere for any use. All material discussed here is supplied strictly as a research reagent.

References

References sourced via PubMed.

1. Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16. DOI | PubMed
2. Ogrodnik M, Evans SA, Fielder E, et al. Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice. Aging Cell. 2021;20(2):e13296. DOI | PubMed
3. Born E, Lipskaia L, Breau M, et al. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation. 2023;147(8):650-666. DOI | PubMed

Disclaimer: This article is provided for informational and scientific reference purposes only and describes published preclinical literature. All products referenced are sold strictly as research chemicals for laboratory use only. They are not intended for human or veterinary use, and nothing here constitutes medical advice or a health claim of any kind.